FIG. 6.

Zosteriform spread model. Comparison of BAY 57-1293 with valacyclovir in the zosteriform spread model. C3H/TifBom-hr female mice were dermally infected with 10⁶ PFU of HSV-2G, and the disease score (the mean for 10 animals per group) was subsequently recorded on a daily basis by use of the scoring system described in Materials and Methods. Delayed oral treatment (t.i.d.) with 15 and 60 mg of BAY 57-1293 per kg and 60 and 240 mg of valacyclovir per kg was commenced on day 3 postinfection and continued until day 7 postinfection. (a) Zosteriform lesions for typical animals at the start of treatment (day 3 postinfection) and after 4 days of treatment (day 6 postinfection) with placebo, valacyclovir, or BAY 57-1293. Ten animals from each group were used. (b) The mean disease score for each treatment group was calculated at different times postinfection and plotted versus the time postinfection. The cumulative disease scores were calculated and compared between treatment groups by one-way analysis of variance. In order to account for multiple tests, the resulting P values were adjusted by the Bonferroni-Holm method. Treatment with 15 mg of BAY 57-1293 per kg t.i.d. was more effective than treatment with 240 mg of valacyclovir per kg t.i.d. (P < 0.011). (c) Survival curves for the various treatment groups.